Camp4 Therapeutics CorpCAMPEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Camp4 Therapeutics Corp is a clinical-stage biotechnology company focused on developing innovative RNA-targeted therapies for rare genetic diseases. It leverages its proprietary regulatory RNA mapping platform to identify novel therapeutic targets, primarily serving patients with unmet medical needs across North America and Europe.
CAMP Q3 FY2025 Key Financial Metrics
Revenue
$795.0K
Gross Profit
N/A
Operating Profit
$-13.7M
Net Profit
$-15.1M
Gross Margin
N/A
Operating Margin
-1717.1%
Net Margin
-1899.2%
YoY Growth
N/A
EPS
$-0.55
Camp4 Therapeutics Corp Q3 FY2025 Financial Summary
Camp4 Therapeutics Corp reported revenue of $795.0K for Q3 FY2025, with a net profit of $-15.1M (down 12.0% YoY) (-1899.2% margin).
Key Financial Metrics
| Total Revenue | $795.0K |
|---|---|
| Net Profit | $-15.1M |
| Gross Margin | N/A |
| Operating Margin | -1717.1% |
| Report Period | Q3 FY2025 |
Camp4 Therapeutics Corp Quarterly Revenue & Net Profit History
Camp4 Therapeutics Corp results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $795.0K | — | $-15.1M | -1899.2% |
| Q2 FY2025 | $1.5M | — | $-12.6M | -840.8% |
| Q1 FY2025 | $858.0K | — | $-12.4M | -1449.1% |
| Q3 FY2024 | $0 | — | $-13.5M | N/A |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $858000 | $1.5M | $795000 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $21.4M | $62.8M | $51.3M | $86.4M |
| Liabilities | $18.2M | $11.2M | $11.3M | $27.7M |
| Equity | $-159.0M | $51.6M | $40.0M | $58.7M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Operating CF | $-14.3M | $-10.3M | $-11.2M |